In most cases, marker expression was relatively homogeneous within one GBM, while only 4/12 markers (CD133, CD44, CD15, and A2B5) showed relevant intra-tumoral heterogeneity (Fig. 1c, Supplementary Fig. 3B), which would be expected from a bona fide CSC marker. This evidence concerns the gene CD44 and glioblastoma.